Next Article in Journal
Efficient Synthesis, Structural Characterization, Antibacterial Assessment, ADME-Tox Analysis, Molecular Docking and Molecular Dynamics Simulations of New Functionalized Isoxazoles
Next Article in Special Issue
Quinoxaline 1,4-di-N-oxide Derivatives as New Antinocardial Agents
Previous Article in Journal
Preparation and Properties of Composite Double-Network Gel for Inhibiting Coal Spontaneous Combustion
Previous Article in Special Issue
The Nitrofuran-Warhead-Equipped Spirocyclic Azetidines Show Excellent Activity against Mycobacterium tuberculosis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 29
Issue 14
10.3390/molecules29143364
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Molecular Periphery Design Allows Control of the New Nitrofurans Antimicrobial Selectivity

by
Lyubov Vinogradova
1,
Alexey Lukin
1,
Kristina Komarova
1,
Maxim Zhuravlev
1,
Artem Fadeev
1,
Mikhail Chudinov
1,*,
Elizaveta Rogacheva
2,
Lyudmila Kraeva
2,
Maxim Gureev
3,
Yuri Porozov
4,5,
Marine Dogonadze
6 and
Tatiana Vinogradova
6
1
Lomonosov Institute of Fine Chemical Technologies, MIREA—Russian Technological University, 119454 Moscow, Russia
2
Pasteur Institute of Epidemiology and Microbiology, 197101 Saint Petersburg, Russia
3
Institute of Cytology, Russian Academy of Sciences, Tikhoretsky Ave. 4, 194064 Saint Petersburg, Russia
4
Laboratory of Angiopathology, The Institute of General Pathology and Pathophysiology, 8 Baltiyskaya Street, 125315 Moscow, Russia
5
Advitam Laboratory, Mihaila Shushkaloviћа 13, 11030 Belgrade, Serbia
6
Saint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of the Russian Federation, 191036 Saint Petersburg, Russia
*
Author to whom correspondence should be addressed.
Molecules 2024, 29(14), 3364; https://doi.org/10.3390/molecules29143364
Submission received: 24 May 2024 / Revised: 12 July 2024 / Accepted: 13 July 2024 / Published: 17 July 2024
(This article belongs to the Special Issue Advances in Antibacterial Molecules)
Browse Figures
Versions Notes

Abstract

:
A series of 13 new 3-substituted 5-(5-nitro-2-furyl)-1,2,4-oxadiazoles was synthesized from different aminonitriles. All compounds were screened in the disc diffusion test at a 100 μg/mL concentration to determine the bacterial growth inhibition zone presence and diameter, and then the minimum inhibitory concentrations (MICs) were determined for the most active compounds by serial dilution. The compounds showed antibacterial activity against ESKAPE bacteria, predominantly suppressing the growth of 5 species out of the panel. Some compounds had similar or lower MICs against ESKAPE pathogens compared to ciprofloxacin, nitrofurantoin, and furazidin. In particular, 3-azetidin-3-yl-5-(5-nitro-2-furyl)-1,2,4-oxadiazole (2h) inhibited S. aureus at a concentration lower than all comparators. Compound 2e (5-(5-nitro-2-furyl)-3-[4-(pyrrolidin-3-yloxy)phenyl]-1,2,4-oxadiazole) was active against Gram-positive ESKAPE pathogens as well as M. tuberculosis. Differences in the molecular periphery led to high selectivity for the compounds. The induced-fit docking (IFD) modeling technique was applied to in silico research. Molecular docking results indicated the targeting of compounds against various nitrofuran-associated biological targets.

Graphical Abstract

1. Introduction

Antibiotic development efforts are most often focused on discovering broad-spectrum drugs that are simultaneously active against many pathogens. The undeniable advantages of these drugs also have a black side. The structure of biological targets varies significantly among different microbial species. As a result, broad-spectrum antibiotics aren’t able to combat various infections with equal efficiency. Such medications are often prescribed without accurately identifying the infection and are used off-label. This is the root of the antibiotic resistance problem [1], which makes antibiotic development economically unjustified [2]. An alternative to broad-spectrum antibiotics are so-called precision antibiotics. Precision antimicrobials selectively kill only one pathogen with the least off-target effects. This makes them less likely to cause resistance than broad-spectrum antibiotics. Additionally, since drugs that target only one pathogen do not use the same metabolic pathways, they are less likely to cause harm to the host’s resident microbes [3]. However, the search for antimicrobial agents that are selectively active against one pathogen seems even less economically reasonable.
The goal of our work was to demonstrate that excellent selectivity for a series of compounds against diverse microbial targets can be achieved by fine-tuning their molecular periphery. One of the research areas in our laboratory is new antimicrobials among nitro heterocycles, including nitrofurans [4,5] and nitroimidazoles [6]. Nitrofurans (NFs) have been used clinically since the 1960s. The antibiotic effect of NF follows a stepwise process involving activation by reduction, catalyzed by microbial azoreductases [7,8] and nitroreductases [9]. In anaerobic conditions, type I reductases catalyze the reduction of NFs to produce cytotoxic hydroxylamine. While in aerobic conditions, nitroreduction catalyzed by type II reductases produces reactive oxygen and nitrogen species, causing oxidative stress and the ultimate death of bacteria [10]. Specificity to certain reductases determines the selectivity of NF action. For these molecules, another type of action is also possible: the direct inhibition of target proteins [11,12].
Nitrofuran antibiotics are widely used in clinical practice against anaerobic infections. There are also many promising compounds based on the nitrofuran “warhead” that are active against M. tuberculosis (MTB) [10,13,14,15]. The classical NFs have a wide activity spectrum as well as high toxicity. Most clinical NFs (Figure 1) contain a “warhead” with an azo group derived from 5-nitro-2-furaldehyde. The previously described substitution of an azo group with an isosteric heterocycle can render these compounds non-cytotoxic in general, but it can also direct their activity to a specific type of bacterial target and does not affect the entire microbiome [5,14,15,16,17].
Thirteen new compounds were synthesized according to Scheme 1. In target compounds 2a–m, the azo group was replaced by an isosteric oxadiazole ring. A range of alkylamine moieties were added to the previously tested design, which combined a 1,2,4-oxadiazole ring and a 5-nitrofuran pharmacophore. All new nitrofurans were tested against ESKAPE [18] and MTB pathogens. The previously reported conjugates of 1,2,4-oxadiazoles with nitrofurans (Figure 1) [15] displayed remarkable selectivity against MTB (HRv37 strain). However, their activity against other Gram-positive and Gram-negative pathogens was not observed. By contrast, certain compounds tested within the 2a–m series shared structural features and demonstrated selectivity against individual pathogens of the ESKAPE panel and MTB. Molecular docking of these molecules with the most likely target proteins was used for this phenomenon explanation.

2. Results and Discussion

2.1. Chemistry

The synthesis of compounds 2a–m was carried out in two steps using commercially available or previously synthesized nitriles [19,20,21]. At the first step, nitriles were treated with aqueous hydroxylamine to obtain amidoximes 1a–m. Compounds 1a–m were acylated with 5-nitro-2-furoic acid and cyclized one-pot into the target 3-substituted 5-(5-nitro-2-furyl)-1,2,4-oxadiazoles 2a–m. The proposed cyclization method turned out to be the only effective way to obtain the target compounds. The other approaches described [22,23], such as cyclization of acylamidoximes in pyridine or catalysis with tetrabutyl ammonium fluoride, resulted in decomposition products only. The purity of the final compounds according to TLC and NMR data was sufficient for biological testing (at least 95%).

2.2. Antibacterial Activity

Nitrofurans 2a–m were tested against Gram-positive (S. aureus and E. faecium) or Gram-negative (P. aeruginosa, A. baumannii, K. pneumoniae, and E. cloacae) pathogens of the ESKAPE panel. The clinically used antibiotic ciprofloxacin was used as a positive control and comparator. All compounds were screened at a 100 μg/mL concentration to determine the presence and diameter of the bacterial growth inhibition zone around the drug-treated disk (Table 1). Compounds 2c,h that displayed growth inhibition for most pathogens on the ESKAPE panel were tested in serial dilution mode to determine the minimum inhibitory concentration (MIC). All compounds 2a–m were tested against MTB in serial dilution mode, and MICs were determined (Table 2).
Most substances in the series exhibit antibacterial activity predominantly against Gram-positive bacteria (Table 1 and Table 2). Interestingly, they act on S. aureus but do not show an effect on E. faecium. Compound 2k is active against A. baumannii, 2a against P. aeruginosa, and 2b against E. cloacae. Compound 2e is active against M. tuberculosis and two Gram-positive and one Gram-negative pathogens.

2.3. Molecular Modeling

The calculations were performed for five targets belonging to four microbial species. Based on the results of experiments as well as data on the studied microorganisms, a pool of potential targets with which the studied compounds can interact was formed. These are azoreductase (AzoR), oxygen-insensitive NADPH nitroreductase (NfsA), oxygen-insensitive NAD(P)H nitroreductase (NfsB), deazaflavin-dependent nitroreductase from M. tuberculosis (Ddn), and phosphoglycerate kinase (Pgk). AzoR, NfsA, NfsB, and Ddn are conventional targets of nitrofuran antibiotics, as they reduce the nitrofuran moiety to highly reactive intermediates that inhibit the citric acid cycle as well as the synthesis of DNA, RNA, and proteins [25]. Pgk is not usually considered a possible target for nitrofurans, but there is an example of enzyme inhibition by a nitrofuran compound [26]. Phosphoglycerate kinase from A. baumannii has been selected as a potential target for antibiotic development [27]. It is worth noting that the protein structures were matched to the bacteria in question: P. aeruginosa, S. aureus, A. baumannii, and M. tuberculosis.
The docking results are summarized in Table 3, where a color-coded scheme of compound differentiation with experimentally derived characteristics of affinity or lack thereof in the context of site- and species-specific interactions is introduced. The low-active substances 2b, l, and m were excluded from the calculations.
The experiments performed demonstrated that the compounds under study possess a number of remarkable properties. These properties have been interpreted through the utilization of molecular modeling techniques, enabling the identification of a priority target. This, in turn, illuminates the subsequent targeting of the compounds, taking into consideration both the nature of the target and species specificity.
Compounds 2c and 2h showed high antibacterial activity against ESKAPE pathogens but not antituberculosis activity. Compound 2c showed high affinity for the Pgk protein in P. aeruginosa and A. baumannii, as well as for AzoR in S. aureus and A. baumannii. The interaction of 2c with NfsA was moderate, despite the high quality of the binding pose, and the scores of the evaluation function are worse than those with AzoR. The affinity of 2c to the NfsB protein was low, as was the quality of the binding pose. Apparently, the decrease in the intensity of lipophilic contacts causes the leaching, which in turn reduces the molecule’s affinity to the protein’s active site. Ligand interaction diagrams of 2c with azoreductase (potential principal target) and NfsB (least likely target for ligand binding) are shown in Supporting Information (Figure S4). Compound 2h demonstrated pronounced species specificity against S. aureus. These calculations predict the most effective interaction with azoreductase (AzoR) and oxygen-insensitive NADPH nitroreductase (NfsA). However, the calculations also showed that 2h was capable of interacting with similar targets in other microorganisms considered. As in the previous case, NfsB was the least promising target for interaction (Table 3). The binding affinity of compound 2h to azoreductase in all microorganisms was associated with tighter lipophilic contacts. Additionally, it is important to note the frequent occurrence of π-stacking between the furan and oxadiazole cycles with tyrosines and phenylalanines, which also aids in the proper orientation of the nitro group within the protein’s catalytic region (Figure 2).
The active compounds 2c and 2h possess an orienting π-stacking interaction with Tyr119 of AzoR (Figure 2 and Figure 3), which ensures that the nitro group is present near the reactive flavin nitrogen of the mononucleotide (FMN). These compounds do not have the aforementioned drawbacks.
The next target is NfsA, which is present in all bacterial species. Nitrofurantoin is the main interactant and control compound. Calculations have shown that the leader compounds 2c and 2h have selective affinity to NfsA, depending on the pathogen. Compounds 2d and 2g, which did not show antibacterial activity against ESKAPE pathogens, demonstrated poor binding pose parameters and did not reproduce the key pharmacophore characteristics of the control compound.
Compound 2с formed salt bridges with arginine and lysine in the same manner as the control and also had the necessary lipophilic contacts that determine the correct orientation of the ligand in the active site of the protein. Notably, 2c had the highest affinity for NfsA from A. baumannii, followed by S. aureus. Based on the ligand–protein interaction diagrams, it is clear that 2c has the advantage of an extended network of lipophilic contacts (see Supporting Information, Figure S8).
Compounds 2a, 2c, 2e, 2f, 2h, 2i, and 2j showed pronounced species specificity against S. aureus. The above compounds have a rather high generalized affinity for the targets considered in the context of S. aureus. However, a variation in binding selectivity was observed in terms of binding pose quality and reproduction of pharmacophore characteristics. For example, binding to Pgk was not specific for all the above compounds due to their incorrect binding poses (Table 3, section Pgk@S. aureus).
In the context of S. aureus AzoR azoreductase, we observed high predicted affinity in terms of scoring function value as well as high binding pose quality (which corresponded to the pharmacophore characteristics for nitrofurantoin and other nitrofuran-based antibiotics) for compounds 2c, 2f, 2h, and 2i. The others, except the inactive ones, showed moderate binding pose quality with comparable scoring function values (see Table 3, section AzoR@S. aureus).
For NfsA of S. aureus, the picture was slightly different: compounds 2e and 2f were washed out due to poor quality protein–ligand binding. At the same time, the best-performing compounds were: 2a, 2h, and 2i. They had the best binding pose and at the same time, high values of the scoring function (see Supporting Information, Table S4).
S. aureus phosphoglycerate kinase (Pgk) did not fall into the pool of potential targets of the compounds considered, as all compounds showed poor quality of docking solutions despite rather high values of predicted small molecule affinity to the active site (see Table 3, section Pgk@S. aureus).
In contrast, the situation with NfsB was positive: all the compounds listed showed high docking solution quality in the NfsB active cleft, with structures 2f, 2i, and 2k as the best-fitting compounds.
The selectivity of 2k against A. baumannii is very interesting, since this pathogen is very important from the point of view of the treatment of nosocomial infections [28]. According to the combination of scoring function value and binding quality, the best target of 2k was Pgk (Table 3). AzoR may serve as a second synergetic target. The binding to NfsB was energetically favorable but violated the control structure binding pose (Figure 4C).
In the case of interaction with Pgk, 2k reproduced the binding mode of the reference compound with experimentally demonstrated affinity (see Supporting Information, Figure S2). The key was the orientation of the nitrofuran moiety towards the glycine-rich protein site (catalytic cavity of the protein) and the reproducibility of the necessary lipophilic contacts (Figure 4A).
Compound 2a, selective against P. aeruginosa, had affinity to targets in the series: AzoR > Pgk > NfsA > NfsB (affinity level descending). The interaction was most qualitatively realized with AzoR and Pgk (in terms of reproducibility of the control structure binding mode as well as scoring function values, see Table 3). NfsA is rather a collateral target with low predicted affinity, although it can provide a potential synergistic effect due to a possible multi-target interaction.
M. tuberculosis has its own specific targets, so it was decided to look at them separately and find the most likely ones. For the calculations, we used positive and negative controls as well as compound 2e directly. Initially, only the structure of the Ddn protein (desaflavin-dependent nitroreductase) was considered. Compounds 2c, 2d, 2g, and 2h gave no docking results (the program reported that docking of this compound was not possible at the selected active site). On the other hand, the remaining structures showed a stable interaction with a high clustering of solutions, the best among them being 2e and having the leading scoring function values (Table 3, section Ddn@M. tuberculosis). The 2e nitrofuran group is located in the protein’s catalytic region, where the flavin mononucleotide (FMN) molecule is also present. This interaction with the nitro group determines the target activity during its reduction process. The nitrofuran functional group forms a π-stacking interaction with the aromatic core of FMN, contributing to the target activity. Additionally, the 3-phenoxypyrrolidine fragment at the oxadiazole core stimulates lipophilic contacts with leucines/isoleucines and phenylalanines in the protein’s active cavity (see Figure 5B).
However, M. tuberculosis has more promising targets than just nitroreductases. Analysis of the literature has revealed the presence of at least three additional targets:
(1)
The HTH-type transcriptional regulator EthR interacts with linezolid, as indicated by Pdb: 5NZ0. Inhibition of EthR has been shown to enhance the effectiveness of antibiotics and reduce drug resistance [29];
(2)
Arylamine N-acetyltransferase (TBNAT, Pdb: 4BGF) is responsible for the intracellular survival of M. tuberculosis within macrophages. It has been identified as a promising target [30,31]. In 2020, it was discovered that nitrofurans could inhibit it. Prior to this, there had been limited research on the subject [32].
(3)
Enoyl reductase (InhA, PDB: 4TZK) is a protein associated with antibiotic resistance, making it an attractive target for small-molecule design [33,34].
All of the targets considered are present in the RCSB Protein Data Bank, some of them are in complex with small-molecule inhibitors (respectively, there is a control). After preparing the protein structures (error correction, solvent removal, GridBox calculation based on ligand or literature data), the investigated compounds were docked into the protein structure. These compounds included 2e itself, active 2d, 2k, and 2h, inactive 2a, 2c, and 2g. The results are presented in Table 4.
Based on the modeling results, it can be concluded that EthR is the most likely target. This is because 2e binds to the active cavity of the protein better than any other structure, as indicated by the scoring function. The lipophilic contacts with aromatic amino acids, including Phe110/184, Trp138/145, Leu183, and Ile107 (Figure 6), played a significant role in this binding. In all other compounds, the nitro group was oriented in the opposite direction (towards Tyr148). The absence of phenyl (as in 2e) ensures redistribution of lipophilic contacts, resulting in a more rational binding mode (see Figure 6). This explains why 2e had a higher predicted affinity to EthR compared to the other structures (see Table 4).
Regarding the InhA protein, all compounds, except 2g, had high scores on the evaluation function that describes their potential affinity for the protein. However, we observed a leaching of 2g in terms of binding pose quality. This was caused by steric factors, as the methoxyethyl substituent at the quaternary carbon of the piperidine fragment created steric complications for the binding mode of the compound in the same manner as the control (green). Compound 2d was inactive and formed an unstable interaction, characterized by weak docking solutions clustering. All other compounds (2a, 2c, 2e, 2h, and 2k) binded identically. The nitro group was oriented similarly to the lipophilic dichlorophenyl fragment of the control compound, while the alicyclic fragments (and the aromatic one from 2e) reproduced the binding mode of the cyclohexyl substituent of the control structure (see Figure S12). Compound 2e was the leading candidate in the series, as it accurately reproduced the binding mode of the control compound and had the highest score.
No stable ligand–protein complexes were formed with TBNAT protein, and all structures exhibited low affinity for the active cavity. Therefore, TBNAT protein was not a priority target for compound 2e, which had specific activity against M. tuberculosis.

3. Materials and Methods

3.1. Chemistry

All reactions were conducted on oven-dried glassware in a nitrogen atmosphere. Melting points were measured with a Buchi В-520 melting point apparatus (Buchi Labortechnik AG, Flawil, Switzerland) and were not corrected. The NMR spectra were recorded on a Bruker MSL-300 spectrometer (Bruker Corporation, MS, USA) at 25 °C (1H: 300 MHz; 13C: 75 MHz; chemical shifts are reported as parts per million (δ, ppm)) in dimethyl sulfoxide (DMSO-d6); the residual solvent peak used as an internal standard: 2.50 ppm for 1H and 40.01 ppm for 13C, respectively. Mass spectra were recorded using the Shimadzu LCMS-2020 system with ESI. High-resolution mass spectra (HRMS) were recorded using a Bruker microTOF spectrometer (Bruker Corporation, MS, USA) (ionization by electrospray, positive ion detection). Analytical thin-layer chromatography (TLC) was carried out on Sorbfil UV-254 silica gel plates (Imid Ltd., Moscow, Russia) using appropriate mixtures of solvent. The compounds were visualized with short-wavelength UV light. Column chromatography was performed on silica gel 60 (230–400 mesh). All reagents and solvents were obtained from commercial sources and used without further purification.

3.1.1. General Procedure for the Synthesis of Compounds 1a–m

To 5 mL of a 50% aqueous solution of NH2OH, the corresponding nitrile (0.01 mol) was added with stirring. MeOH was added dropwise to the resulting suspension until the precipitate was completely dissolved. After completion of the reaction (TLC control, 12–24 h), the precipitate that formed was filtered off and, if necessary, recrystallized from EtOH.
  • tert-butyl 4-[(hydroxyamino)(imino)methyl]piperidine-1-carboxylate (1a)
Yield 1.84 g (76%), white solid, m.p. 147–147.5 °С. 1H NMR (300 MHz, DMSO-d6) δ 8.78 (s, 1H), 5.28 (s, 2H), 3.94 (d, J = 13.0 Hz, 2H), 2.69 (t, J = 11.6 Hz, 2H), 2.26–2.02 (m, 1H), 1.66 (dd, J = 19.6, 8.9 Hz, 2H), 1.54–1.22 (m, 11H); 13C NMR (75 MHz, DMSO-d6) δ 155.61, 154.24, 78.88, 43.76, 38.57, 29.46, 28.50. LСMS (ESI): m/z (M + H+) calcd, 244.1; found, 244.2.
  • tert-butyl 3-[(hydroxyamino)(imino)methyl]piperidine-1-carboxylate (1b)
Yield 1.75 g (72%), white solid, m.p. 134–134.5 °С. 1H NMR (300 MHz, DMSO-d6) δ 8.85 (s, 1H), 5.32 (s, 2H), 4.00–3.80 (m, 2H), 2.91–2.55 (m, 2H), 2.05 (tt, J = 11.5, 3.7 Hz, 1H), 1.89 (d, J = 12.6 Hz, 1H), 1.69–1.57 (m, 1H), 1.55–1.22 (m, 12H); 13C NMR (75 MHz, DMSO-d6) δ 154.27, 78.94, 60.15, 55.26, 28.95, 28.44, 25.13, 21.12, 14.45. LСMS (ESI): m/z (M + H+) calcd, 244.1; found, 244.2.
  • tert-butyl [3-(hydroxyamino)-3-iminopropyl]methylcarbamate (1c)
Yield 1.7 g (78%), white solid, m.p. 150.5–151 °С. 1H NMR (300 MHz, DMSO-d6) δ 8.81 (s, 1H), 5.35 (s, 2H), 3.32 (t, J = 7.3 Hz, 2H), 2.76 (s, 3H), 2.14 (t, J = 7.3 Hz, 2H), 1.38 (s, 9H); 13C NMR (75 MHz, DMSO-d6) δ 155.00, 151.06, 78.67, 46.53, 34.27, 28.43. LСMS (ESI): m/z (M + H+) calcd, 218.1; found, 218.2.
  • tert-butyl [2-(hydroxyamino)-2-iminoethyl]methylcarbamate (1d)
Yield 10 g (92%), white solid, m.p. 173–173.5 °С. 1H NMR (300 MHz, DMSO-d6) δ 9.11 (s, 1H), 5.16 (s, 2H), 3.72 (s, 2H), 2.75 (s, 3H), 1.40 (s, 9H); 13C NMR (75 MHz, DMSO-d6) δ 149.69, 79.30, 48.77, 48.24, 34.43, 28.41. LСMS (ESI): m/z (M + H+) calcd, 204.1; found, 204.2.
  • tert-butyl 3-{4-[(hydroxyamino)(imino)methyl]phenoxy}pyrrolidine-1-carboxylate (1e)
Yield 1.95 g (61%), white solid, m.p. 198–198.5 °С. 1H NMR (300 MHz, DMSO-d6) δ 9.45 (s, 1H), 7.60 (d, J = 8.8 Hz, 2H), 6.93 (d, J = 8.8 Hz, 2H), 5.70 (s, 2H), 5.02 (s, 1H), 3.53 (s, 1H), 3.48–3.33 (m, 3H), 2.09 (d, J = 19.3 Hz, 2H), 1.39 (s, 9H); 13C NMR (75 MHz, DMSO-d6) δ 154.00, 153.91, 150.90, 127.24, 126.45, 115.28, 78.94, 76.48, 75.61, 51.51, 44.07, 31.12, 30.35, 28.51. LСMS (ESI): m/z (M + H+) calcd, 322.1; found, 322.2.
  • tert-butyl 3-{2-[(hydroxyamino)(imino)methyl]phenoxy}pyrrolidine-1-carboxylate (1f)
Yield 2.08 g (65%), white solid, m.p. 184–184.5 °С. 1H NMR (300 MHz, DMSO-d6) δ 9.43 (s, 1H), 7.43 (dd, J = 7.6, 1.7 Hz, 1H), 7.35 (ddd, J = 8.4, 7.4, 1.8 Hz, 1H), 7.07 (d, J = 8.1 Hz, 1H), 6.97 (td, J = 7.5, 0.9 Hz, 1H), 5.52 (s, 2H), 5.02 (s, 1H), 3.55 (s, 1H), 3.50–3.22 (m, 3H), 2.08 (s, 2H), 1.40 (s, 9H); 13C NMR (75 MHz, DMSO-d6) δ 155.10, 154.01, 151.18, 130.54, 123.96, 121.17, 114.70, 78.91, 77.51, 76.66, 51.67, 44.33, 31.26, 30.48, 28.53. LСMS (ESI): m/z (M + H+) calcd, 322.1; found, 322.2.
  • tert-butyl 4-[(hydroxyamino)(imino)methyl]-4-(2-methoxyethyl)piperidine-1-carboxylate (1g)
Yield 2.1 g (70%), white solid, m.p. 120–120.5 °С. 1H NMR (300 MHz, DMSO-d6) δ 9.06 (s, 1H)-слабый, 7.09 (d, J = 76.3 Hz, 1H), 5.31 (s, 1H), 3.71–3.45 (m, 2H), 3.31 (s, 1H), 3.25 (q, J = 7.6 Hz, 2H), 3.17 (d, J = 2.5 Hz, 3H), 3.08–2.75 (m, 2H), 1.94 (d, J = 13.7 Hz, 2H), 1.69 (t, J = 7.3 Hz, 2H), 1.38 (s, 9H), 1.27 (t, J = 10.4 Hz, 2H); 13C NMR (75 MHz, DMSO-d6) δ 176.66, 154.43, 154.31, 154.03, 78.85, 68.66, 58.26, 43.36, 33.39, 28.44. LСMS (ESI): m/z (M + H+) calcd, 302.2; found, 302.2.
  • tert-butyl 3-[(hydroxyamino)(imino)methyl]azetidine-1-carboxylate (1h)
Yield 2.27 g (72%), white solid, m.p. 170–170.5 °С. 1H NMR (300 MHz, DMSO-d6) δ 9.07 (s, 1H), 5.43 (s, 2H), 3.91 (dd, J = 9.9, 7.0 Hz, 4H), 3.24–3.09 (m, 1H), 1.37 (s, 9H); 13C NMR (75 MHz, DMSO-d6) δ 155.93, 152.28, 78.90, 55.23, 29.57, 28.42. LСMS (ESI): m/z (M + H+) calcd, 316.1; found, 316.2.
  • tert-butyl 2-[(hydroxyamino)(imino)methyl]piperidine-1-carboxylate (1i)
Yield 2.26 g (93%), white solid, m.p. 154–154.5 °С. 1H NMR (300 MHz, DMSO-d6) δ 9.13 (s, 1H), 5.14 (s, 2H), 4.64 (s, 1H), 3.87–3.67 (m, 1H), 2.96 (t, J = 12.4 Hz, 1H), 2.03 (t, J = 12.1 Hz, 1H), 1.67–1.07 (m, 14H); 13C NMR (75 MHz, DMSO-d6) δ 155.09, 151.39, 79.07, 51.07, 41.33, 28.48, 26.68, 25.07, 19.81. LСMS (ESI): m/z (M + H+) calcd, 244.1; found, 244.2.
  • tert-butyl 4-[(hydroxyamino)(imino)methyl]-4-methylpiperidine-1-carboxylate (1j)
Yield 1.72 g (67%), white solid, m.p. 178.5–179 °С. 1H NMR (300 MHz, DMSO-d6) δ 8.97 (s, 1H), 5.26 (s, 2H), 3.47 (dt, J = 9.2, 4.3 Hz, 2H), 3.10 (t, J = 10.3 Hz, 2H), 1.88 (t, J = 16.7 Hz, 2H), 1.38 (s, J = 4.9 Hz, 9H), 1.22 (ddd, J = 14.6, 9.1, 4.3 Hz, 2H), 1.10 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 156.48, 154.46, 109.53, 78.76, 36.73, 34.42, 28.50, 26.83. LСMS (ESI): m/z (M + H+) calcd, 258.1; found, 258.2.
  • tert-butyl 3-[2-(hydroxyamino)-2-iminoethyl]pyrrolidine-1-carboxylate (1k)
Yield 1.58 g (65%), white solid, m.p. 92–92.5 °С. 1H NMR (300 MHz, DMSO-d6) δ 8.76 (s, 1H), 5.34 (s, 2H), 3.34 (tdd, J = 12.1, 9.3, 3.8 Hz, 2H), 2.84 (dd, J = 10.5, 7.7 Hz, 1H), 2.36 (dd, J = 29.8, 6.6 Hz, 1H), 2.16–1.73 (m, 3H), 1.63–1.42 (m, 1H), 1.38 (s, 9H); 13C NMR (75 MHz, DMSO-d6) δ 153.92, 152.10, 78.52, 78.46, 51.22, 50.99, 48.97, 45.46, 45.33, 36.35, 35.51, 34.41, 31.24, 30.56, 28.56. LСMS (ESI): m/z (M + H+) calcd, 244.1; found, 244.2.
  • tert-butyl 3-[(hydroxyamino)(imino)methyl]pyrrolidine-1-carboxylate (1l)
Yield 1.92 g (84%), white solid, m.p. 158–158.5 °С. 1H NMR (300 MHz, DMSO-d6) δ 8.94 (s, 1H), 5.40 (s, 2H), 3.53–3.03 (m, 4H), 2.78 (dd, J = 15.1, 7.6 Hz, 1H), 2.07–1.78 (m, 2H), 1.39 (s, 9H); 13C NMR (75 MHz, DMSO-d6) δ 153.81, 152.52, 152.47, 78.52, 48.76, 48.56, 45.61, 45.45, 29.16, 28.55, 28.39, 19.31. LСMS (ESI): m/z (M + H+) calcd, 230.1; found, 230.2.
  • tert-butyl 3-[(hydroxyamino)(imino)methyl]-3-(2-methoxyethyl)piperidine-1-carboxylate (1m)
Yield 2.41 g (80%), white solid, m.p. 104–104.5 °С. 1H NMR (300 MHz, DMSO-d6) δ 9.01 (s, 1H), 5.29 (s, 2H), 3.64 (s, 2H), 3.39–3.23 (m, 3H), 2.81 (s, 1H), 1.91–1.56 (m, 5H), 1.54–1.30 (m, 12H); 13C NMR (75 MHz, DMSO-d6) δ 155.27, 154.35, 78.89, 69.22, 58.25, 49.07. LСMS (ESI): m/z (M + H+) calcd, 302.2; found, 302.2.

3.1.2. General Procedure for the Synthesis of Compounds 2a–m

To a solution of 5-nitro-2-furoic acid (0.66 g, 0.42 mmol) in DMF (10 mL) at 0 °C, CDI (0.71 g, 0.44 mmol) was added in portions with stirring. The reaction mixture was stirred for 30 min, and then a solution of 0.4 mmol of the corresponding amidoxime in DMF (5 mL) was added dropwise. The reaction mass was stirred overnight at room temperature, then heated to 90 °C and stirred for 4 h. The reaction mixture was poured onto ice, and the precipitate that formed was filtered off and dried. Then 5 mL of a 3 M HCl/dioxane solution was added to the resulting precipitate, stirred overnight, evaporated, and the residue was crystallized from EtOH.
  • 4-[5-(5-nitro-2-furyl)-1,2,4-oxadiazol-3-yl]piperidine hydrochloride (2a)
Yield 0.6 g (50%), white solid, m.p. 176–176.5 °С. 1H NMR (300 MHz, DMSO-d6) δ 8.99 (s, 2H), 7.96 (d, J = 4.0 Hz, 1H), 7.89 (d, J = 4.0 Hz, 1H), 3.07 (t, J = 11.7 Hz, 2H), 2.17 (dd, J = 14.1, 2.8 Hz, 2H), 2.06–1.88 (m, 2H); 13C NMR (75 MHz, DMSO-d6) δ 173.00, 166.00, 153.38, 140.29, 119.43, 114.20, 42.50, 31.12, 26.20. HRMS (ESI), m/z calcd C11H13N4O4 [M + H+] 265.0936, found 265.0936.
  • 3-[5-(5-nitro-2-furyl)-1,2,4-oxadiazol-3-yl]piperidine hydrochloride (2b)
Yield 0.7 g (59%), white solid, m.p. 166–166.5 °С. 1H NMR (300 MHz, DMSO-d6) δ 9.43 (s, 2H), 7.96 (d, J = 3.9 Hz, 1H), 7.91 (d, J = 4.0 Hz, 1H), 3.61–3.44 (m, 2H), 3.28 (d, J = 11.5 Hz, 1H), 3.15 (s, 1H), 2.94 (s, 1H), 2.15 (d, J = 12.4 Hz, 1H), 1.85 (d, J = 30.5 Hz, 3H), 1.20 (t, J = 7.2 Hz, 1H); 13C NMR (75 MHz, DMSO-d6) δ 171.19, 166.09, 153.43, 140.13, 45.76, 45.16, 43.21, 31.45, 26.52, 21.37, 8.82. HRMS (ESI), m/z calcd C11H13N4O4 [M + H+] 265.0936, found 265.0935.
  • N-methyl-2-[5-(5-nitro-2-furyl)-1,2,4-oxadiazol-3-yl]ethanamine hydrochloride (2c)
Yield 0.61 g (56%), white solid, m.p. 178.5–179 °С. 1H NMR (300 MHz, DMSO-d6) δ 9.26 (s, 2H), 7.96 (d, J = 4.0 Hz, 1H), 7.91 (d, J = 4.0 Hz, 1H), 3.45–3.21 (m, 4H), 2.59 (t, J = 4.8 Hz, 3H); 13C NMR (75 MHz, DMSO-d6) δ 168.32, 166.08, 153.44, 140.14, 119.57, 114.19, 45.43, 34.53, 32.74, 22.77. HRMS (ESI), m/z calcd C9H11N4O4 [M + H+] 239.0780, found 239.0782.
  • N-methyl-1-[5-(5-nitro-2-furyl)-1,2,4-oxadiazol-3-yl]methanamine hydrochloride (2d)
Yield 0.55 g (53%), white solid, m.p. 229–129.5 °С. 1H NMR (300 MHz, DMSO-d6) δ 9.99 (s, J = 68.9 Hz, 1H), 7.97 (dd, J = 7.7, 3.8 Hz, 2H), 4.52 (s, 2H), 2.68 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 166.64, 165.27, 153.59, 139.68, 120.18, 114.19, 42.31, 33.15. HRMS (ESI), m/z calcd C8H9N4O4 [M + H+] 225.0623, found 225.0623.
  • 5-(5-nitro-2-furyl)-3-[4-(pyrrolidin-3-yloxy)phenyl]-1,2,4-oxadiazole hydrochloride (2e)
Yield 0.7 g (46%), white solid, m.p. 162–163.5 °С. 1H NMR (300 MHz, DMSO-d6) δ 9.77–9.26 (m, 2H), 8.06 (d, J = 8.6 Hz, 2H), 7.98 (d, J = 3.9 Hz, 1H), 7.95 (d, J = 3.9 Hz, 1H), 7.20 (d, J = 8.7 Hz, 2H), 5.28 (s, 1H), 3.51 (s, 1H), 2.23 (dt, J = 61.8, 31.3 Hz, 2H); 13C NMR (75 MHz, DMSO-d6) δ 168.43, 166.14, 159.70, 153.41, 140.32, 129.56, 119.57, 118.68, 116.76, 114.26, 76.26, 50.15, 43.83, 30.93. HRMS (ESI), m/z calcd C16H15N4O5 [M + H+] 343.1042, found 343.1044.
  • 5-(5-nitro-2-furyl)-3-[2-(pyrrolidin-3-yloxy)phenyl]-1,2,4-oxadiazole hydrochloride (2f)
Yield 0.8 g (53%), white solid, m.p. 158–158.5 °С. 1H NMR (300 MHz, DMSO-d6) δ 9.86–8.84 (m, 2H), 8.04–7.97 (m, 2H), 7.96 (d, J = 4.0 Hz, 1H), 7.63 (t, J = 7.1 Hz, 1H), 7.37 (d, J = 8.3 Hz, 1H), 7.24 (t, J = 7.6 Hz, 1H), 5.36 (s, 1H), 3.52 (s, 1H), 3.46–3.37 (m, 3H), 2.30–2.11 (m, 2H); 13C NMR (75 MHz, DMSO-d6) δ 171.66, 169.87, 168.96, 167.40, 167.23, 155.38, 140.40, 133.65, 131.54, 122.37, 119.46, 116.22, 115.86, 114.29, 77.28, 50.13, 44.16, 31.35. HRMS (ESI), m/z calcd C16H15N4O5 [M + H+] 343.1042, found 343.1042.
  • 4-(2-methoxyethyl)-4-[5-(5-nitro-2-furyl)-1,2,4-oxadiazol-3-yl]piperidine hydrochloride (2g)
Yield 0.67 g (47%), white solid, m.p. 165–165.5 °С. 1H NMR (300 MHz, DMSO-d6) δ 9.16–8.57 (m, 2H), 7.96 (d, J = 3.9 Hz, 1H), 7.90 (d, J = 3.8 Hz, 1H), 3.25 (t, J = 6.2 Hz, 3H), 3.09 (s, 3H), 2.89 (s, 2H), 2.36 (d, J = 14.8 Hz, 2H), 2.06–1.84 (m, 4H); 13C NMR (75 MHz, DMSO-d6) δ 173.70, 166.15, 153.33, 140.46, 119.39, 114.22, 67.84, 58.29, 36.56, 30.69. HRMS (ESI), m/z calcd C14H19N4O5 [M + H+] 323.1355, found 323.1352.
  • 3-azetidin-3-yl-5-(5-nitro-2-furyl)-1,2,4-oxadiazole hydrochloride (2h)
Yield 0.62 g (57%), white solid, m.p. 173.5–174 °С. 1H NMR (300 MHz, DMSO-d6) δ 10.11–8.95 (m, 2H), 7.98 (d, J = 3.9 Hz, 1H), 7.94 (d, J = 4.0 Hz, 1H), 4.47–4.09 (m, 5H); 13C NMR (75 MHz, DMSO-d6) δ 170.19, 166.45, 153.51, 139.96, 119.83, 114.21, 48.71, 34.43, 27.82. HRMS (ESI), m/z calcd C9H9N4O4 [M + H+] 237.0623, found 237.0623.
  • 2-[5-(5-nitro-2-furyl)-1,2,4-oxadiazol-3-yl]piperidine hydrochloride (2i)
Yield 0.52 g (43%), white solid, m.p. 160–160.5 °С. 1H NMR (300 MHz, DMSO-d6) δ 10.51–9.08 (m, 2H), 7.98 (q, J = 4.0 Hz, 2H), 4.81 (d, J = 9.0 Hz, 1H), 3.10 (s, 1H), 2.21 (d, J = 10.7 Hz, 1H), 1.98–1.53 (m, 6H); 13C NMR (75 MHz, DMSO-d6) δ 168.67, 166.64, 153.61, 139.62, 120.27, 114.18, 50.79, 44.44, 27.52, 21.59, 21.25. HRMS (ESI), m/z calcd C11H13N4O4 [M + H+] 265.0936, found 265.0935.
  • 4-methyl-4-[5-(5-nitro-2-furyl)-1,2,4-oxadiazol-3-yl]piperidine hydrochloride (2j)
Yield 0.55 g (44%), white solid, m.p. 193–193.5 °С. 1H NMR (300 MHz, DMSO-d6) δ 9.05 (s, 2H), 7.96 (d, J = 4.0 Hz, 1H), 7.90 (d, J = 4.0 Hz, 1H), 3.21 (s, 2H), 2.95 (s, 2H), 2.32 (d, J = 14.3 Hz, 2H), 1.94 (t, J = 12.2 Hz, 2H), 1.38 (s, J = 2.7 Hz, 3H); 13C NMR (75 MHz, DMSO-d6) δ 175.31, 166.19, 153.35, 140.40, 119.43, 114.22, 66.75, 33.99, 31.90, 27.14. HRMS (ESI), m/z calcd C12H15N4O4 [M + H+] 279.1093, found 279.1096.
  • 5-(5-nitro-2-furyl)-3-(pyrrolidin-3-ylmethyl)-1,2,4-oxadiazole hydrochloride (2k)
Yield 0.79 g (66%), white solid, m.p. 166–166.5 °С. 1H NMR (300 MHz, DMSO-d6) δ 9.62–8.78 (m, 2H), 7.96 (d, J = 4.0 Hz, 1H), 7.89 (d, J = 4.0 Hz, 1H), 3.31–3.19 (m, 2H), 3.20–3.08 (m, 1H), 3.02 (d, J = 7.1 Hz, 2H), 2.98–2.83 (m, 1H), 2.80–2.61 (m, 1H), 2.20–2.01 (m, 1H), 1.67 (tt, J = 17.1, 8.6 Hz, 1H); 13C NMR (75 MHz, DMSO-d6) δ 170.08, 165.91, 140.31, 119.41, 114.21, 49.25, 44.58, 35.71, 29.89, 28.23. HRMS (ESI), m/z calcd C11H13N4O4 [M + H+] 265.0936, found 265.0936.
  • 5-(5-nitro-2-furyl)-3-pyrrolidin-3-yl-1,2,4-oxadiazole hydrochloride (2l)
Yield 0.6 g (53%), white solid, m.p. 209–209.5 °С. 1H NMR (300 MHz, DMSO-d6) δ 9.52 (s, 2H), 7.97 (d, J = 4.0 Hz, 1H), 7.92 (d, J = 3.9 Hz, 1H), 3.87 (p, J = 7.7 Hz, 1H), 3.66 (s, 1H), 2.46–2.35 (m, 1H), 2.25–2.12 (m, 1H); 13C NMR (75 MHz, CDCl3) δ 171.03, 166.28, 153.47, 140.07, 119.69, 114.19, 47.66, 44.97, 34.72, 29.36. HRMS (ESI), m/z calcd C10H11N4O4 [M + H+] 251.0780, found 251.0782.
  • 3-(2-methoxyethyl)-4-[5-(5-nitro-2-furyl)-1,2,4-oxadiazol-3-yl]piperidine hydrochloride (2m)
Yield 0.81 g (57%), white solid, m.p. 168–168.5 °С. 1H NMR (300 MHz, DMSO-d6) δ 9.29 (s, 1H), 8.27 (s, 1H), 7.95 (q, J = 4.1 Hz, 2H), 3.69 (d, J = 12.5 Hz, 1H), 3.29–3.14 (m, 5H), 3.01–2.84 (m, 1H), 2.39–2.26 (m, 1H), 2.06–1.64 (m, 6H); 13C NMR (75 MHz, DMSO-d6) δ 172.58, 166.16, 140.20, 119.63, 114.21, 67.62, 58.30, 49.23, 43.38, 30.18, 19.00. HRMS (ESI), m/z calcd C14H19N4O5 [M + H+] 323.1355, found 323.1356.

3.2. Biological Activity Evaluation

Testing was conducted against the following microorganisms: Enterococcus faecalis (ATCC 29812), Staphylococcus aureus (ATCC 25912), Klebsiella pneumoniae (ATCC 19882), Acinetobacter baumannii (948®, a patient-derived strain from the Pasteur Institute’s own collection), Pseudomonas aeruginosa (ATCC 27853), and Enterobacter cloacae (ATCC 13047) for compounds 2a–m and ciprofloxacin (employed as a positive control) using the Kirby–Bauer disk diffusion test under the Standard Operating Procedure of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [35]. Paper disks bearing 5 mg of the tested compounds were used. Solutions of tested compounds in DMSO (1 mg/10 mL) were prepared and diluted to a total volume of 1 mL with deionized water. Aliquots of the resulting solutions (5 µL each) were added to a Petri dish containing Muller–Hilton agar that was inoculated with a bacterial suspension (McFarland OD 1/4 0.5). After the compound solution had dried off, the Petri dish was incubated at 37 °C for 18 h. The bacterial growth inhibition zone diameter around the disc with ciprofloxacin or the compounds’ dried solution circular spot indicated the general susceptibility to a drug being assessed. Thereupon, minimum inhibitory concentrations (MIC, µg/mL) were determined using serial broth dilutions [36]. All measurements were done in triplicate. All compounds 2a–m were tested against the Mycobacterium tuberculosis H37Rv drug-sensitive strain relative to isoniazid that was employed as a positive control. The testing was performed as described previously [37]. All the measurements were done in triplicate.

3.3. In Silico Studies

3.3.1. Target Selection

For each microorganism, a different protein structure was selected (unless they were 100% homologous). The table provided in the Supporting Information (Table S1) summarizes all used protein structures present in the RCSB Protein Data Bank. Most of the proteins were represented as models generated with AlphaFold [38]. In terms of pLDDT, all structures were of acceptable quality when compared to the experimental models (pLDDT > 90 or >70). The considered protein structures underwent a structure alignment procedure to identify active sites for subsequent molecular docking of the studied compounds and parameterization of their affinity to the above targets.

3.3.2. Protein and Ligand Structure Preparation

All proteins (enzymes) were preprocessed before calculations using the protein prep wizard tool from the Schrodinger suite. During preprocessing, errors such as missing amino acid sidechains, incorrect protonation states, missing hydrogens, incorrect bond orders, angles, etc., were fixed. The ligand geometry was generated by the LigPrep module. All molecular modifications were carried out in the OPLS4 force field [39]. Schrödinger Suite 2022-4 was used for calculations.

3.3.3. Induced-Fit Docking of Molecules

IFD docking, a modeling technique that allows the estimation of ligand-induced changes in receptor structure, is a variation in molecular docking that considers the possible mobility of a receptor upon binding to a small molecule within a given radius (in this case, 5 angstroms around the ligand) in a limited way.
Docking grid box calculated based on reference ligand position and size (grid placement on complex ligand centroid, maximum grid side size is 12 Å). In the case of ligand absence docking, the grid box is calculated by residues involved in potential interactions. Twenty poses were generated for each ligand. The best-fitting pose was selected by comparison with the position of the nitrofuran moiety of the reference ligand in the active site of the protein (if available in the PDB files). The clustering of its binding poses was also an important parameter showing ligand binding quality. Additionally, the observed cluster must replicate the pharmacophore characteristics of the reference ligands. This value is shown as stars in parentheses. Three stars: more than 60% clustered docking solutions with RMSD less than 1.5 Å; two stars: 40–60% clustered docking solutions with RMSD less than 3 Å; one star: less than 40% or solutions with no clustering.

4. Conclusions

A series of 13 new 3-substituted 5-(5-nitro-2-furyl)-1,2,4-oxadiazoles was synthesized in two steps. Most of the compounds showed the same activity as ciprofloxacin against S. aureus and some Gram-positive ESKAPE pathogens. Compounds 2c and 2h were definitely the leads. Small structural differences in the molecular periphery lead to high selectivity of compounds against individual pathogens. The significance of these differences was confirmed by molecular docking. Possible biological targets were determined by calculations. Compounds 2e and 2d showed the best anti-tuberculosis activity, while 2d did not show activity against ESKAPE pathogens. The calculations indicated a mechanism of action that is unconventional for nitrofurans, and the better activity of 2e may be explained by a synergistic effect due to a possible multi-target interaction. We found that for the studied compounds, the ligand–protein contacts within their most probable targets can have a big impact on how active they are. In this case, the introduction of a small-sized substituent, as in 2d, led to a loss of activity due to a significant loss of orienting lipophilic contacts, which provided specific recognition of the binding site. On the other hand, in the case of 2g, the substituent at the oxadiazole part of the scaffold had a tendency to form too many lipophilic contacts, which caused significant changes in the way of binding. This can even shift the nitro group from the active center of the protein (in the case of nitroreductases). Regarding the designed compounds, it’s really important to strike a balance between the volume and lipophilicity properties of the introduced substituent.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules29143364/s1, Copies of 1H and 13C NMR spectra; molecular modeling data and visualization. References [7,27,40,41] are cited in the Supplementary Materials.

Author Contributions

Conceptualization, A.L.; methodology, A.L., M.G. and L.K.; formal analysis, A.L. and M.C.; investigation, L.V., K.K., M.Z., A.F., M.G., Y.P., E.R., L.K., M.D. and T.V.; data curation, M.C.; writing—original draft preparation, A.L., M.G. and M.C.; writing—review and editing, M.C. and A.L.; supervision, A.L.; project administration, A.L.; funding acquisition, A.L. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Ministry of Education and Science of Russia; grant number FSFZ-2023-0004 to A.L., K.K. and L.V.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data are contained within the article and Supplementary Materials.

Acknowledgments

This work was also performed using the equipment of the Shared Science and Training Center for Collective Use RTU MIREA and supported by the Ministry of Science and Higher Education of the Russian Federation within the framework of agreement No. 075-15-2021-689 dated 1 September 2021.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Akram, F.; Imtiaz, M.; Haq, I.U. Emergent crisis of antibiotic resistance: A silent pandemic threat to 21(st) century. Microb. Pathog. 2023, 174, 105923. [Google Scholar] [CrossRef] [PubMed]
  2. Miethke, M.; Pieroni, M.; Weber, T.; Brönstrup, M.; Hammann, P.; Halby, L.; Arimondo, P.B.; Glaser, P.; Aigle, B.; Bode, H.B.; et al. Towards the sustainable discovery and development of new antibiotics. Nat. Rev. Chem. 2021, 5, 726–749. [Google Scholar] [CrossRef] [PubMed]
  3. Paharik, A.E.; Schreiber, H.L.t.; Spaulding, C.N.; Dodson, K.W.; Hultgren, S.J. Narrowing the spectrum: The new frontier of precision antimicrobials. Genome Med. 2017, 9, 110. [Google Scholar] [CrossRef]
  4. Rogacheva, E.; Kraeva, L.; Lukin, A.; Vinogradova, L.; Komarova, K.; Chudinov, M.; Gureev, M.; Chupakhin, E. 5-Nitrofuran-Tagged Oxazolyl Pyrazolopiperidines: Synthesis and Activity against ESKAPE Pathogens. Molecules 2023, 28, 6491. [Google Scholar] [CrossRef] [PubMed]
  5. Krasavin, M.; Lukin, A.; Vedekhina, T.; Manicheva, O.; Dogonadze, M.; Vinogradova, T.; Zabolotnykh, N.; Rogacheva, E.; Kraeva, L.; Yablonsky, P. Conjugation of a 5-nitrofuran-2-oyl moiety to aminoalkylimidazoles produces non-toxic nitrofurans that are efficacious in vitro and in vivo against multidrug-resistant Mycobacterium tuberculosis. Eur. J. Med. Chem. 2018, 157, 1115–1126. [Google Scholar] [CrossRef]
  6. Vedekhina, T.S.; Chudinov, M.V.; Lukin, A.Y. Design and synthesis of 4-nitroimidazole derivatives with potential antitubercular activity. Fine Chem. Technol. 2023, 18, 219–229. [Google Scholar] [CrossRef]
  7. Ryan, A.; Kaplan, E.; Laurieri, N.; Lowe, E.; Sim, E. Activation of nitrofurazone by azoreductases: Multiple activities in one enzyme. Sci. Rep. 2011, 1, 63. [Google Scholar] [CrossRef] [PubMed]
  8. Suzuki, H. Remarkable diversification of bacterial azoreductases: Primary sequences, structures, substrates, physiological roles, and biotechnological applications. Appl. Microbiol. Biotechnol. 2019, 103, 3965–3978. [Google Scholar] [CrossRef] [PubMed]
  9. Hoffman, P.S.; Sisson, G.; Croxen, M.A.; Welch, K.; Harman, W.D.; Cremades, N.; Morash, M.G. Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni. Antimicrob. Agents Chemother. 2007, 51, 868–876. [Google Scholar] [CrossRef]
  10. Munoz-Davila, M.J. Role of Old Antibiotics in the Era of Antibiotic Resistance. Highlighted Nitrofurantoin for the Treatment of Lower Urinary Tract Infections. Antibiotics 2014, 3, 39–48. [Google Scholar] [CrossRef] [PubMed]
  11. Polycarpou-Schwarz, M.; Muller, K.; Denger, S.; Riddell, A.; Lewis, J.; Gannon, F.; Reid, G. Thanatop: A novel 5-nitrofuran that is a highly active, cell-permeable inhibitor of topoisomerase II. Cancer. Res. 2007, 67, 4451–4458. [Google Scholar] [CrossRef] [PubMed]
  12. Althagafy, H.S.; El-Aziz, M.K.A.; Ibrahim, I.M.; Abd-Alhameed, E.K.; Hassanein, E.H.M. Pharmacological updates of nifuroxazide: Promising preclinical effects and the underlying molecular mechanisms. Eur. J. Pharmacol. 2023, 951, 175776. [Google Scholar] [CrossRef]
  13. Bauer, A.W.; Kirby, W.M.M.; Sherris, J.C.; Turck, M. Antibiotic Susceptibility Testing by a Standardized Single Disk Method. Am. J. Clin. Pathol. 1966, 45, 493–496. [Google Scholar] [CrossRef] [PubMed]
  14. Zorzi, R.R.; Jorge, S.D.; Palace-Berl, F.; Pasqualoto, K.F.; Bortolozzo Lde, S.; de Castro Siqueira, A.M.; Tavares, L.C. Exploring 5-nitrofuran derivatives against nosocomial pathogens: Synthesis, antimicrobial activity and chemometric analysis. Bioorg. Med. Chem. 2014, 22, 2844–2854. [Google Scholar] [CrossRef] [PubMed]
  15. Krasavin, M.; Shetnev, A.; Panova, V.; Ivanovskyi, S.; Kalinin, S.; Vinogradova, T.; Sharoyko, V.; Yablonsky, P. Hetaryl- and heteroarylvinyl-substituted nitrofurans identified as non-cytotoxic selective antitubercular agents. Mendeleev. Commun. 2022, 32, 452–453. [Google Scholar] [CrossRef]
  16. Picconi, P.; Prabaharan, P.; Auer, J.L.; Sandiford, S.; Cascio, F.; Chowdhury, M.; Hind, C.; Wand, M.E.; Sutton, J.M.; Rahman, K.M. Novel pyridyl nitrofuranyl isoxazolines show antibacterial activity against multiple drug resistant Staphylococcus species. Bioorg. Med. Chem. 2017, 25, 3971–3979. [Google Scholar] [CrossRef] [PubMed]
  17. Ran, K.; Gao, C.; Deng, H.; Lei, Q.; You, X.; Wang, N.; Shi, Y.; Liu, Z.; Wei, W.; Peng, C.; et al. Identification of novel 2-aminothiazole conjugated nitrofuran as antitubercular and antibacterial agents. Bioorg. Med. Chem. Lett. 2016, 26, 3669–3674. [Google Scholar] [CrossRef] [PubMed]
  18. Pendleton, J.N.; Gorman, S.P.; Gilmore, B.F. Clinical relevance of the ESKAPE pathogens. Expert Rev. Anti-Infect. Ther. 2013, 11, 297–308. [Google Scholar] [CrossRef] [PubMed]
  19. Wolkenberg, S.E.; Zhao, Z.; Wisnoski, D.D.; Leister, W.H.; O’Brien, J.; Lemaire, W.; Williams, D.L., Jr.; Jacobson, M.A.; Sur, C.; Kinney, G.G.; et al. Discovery of GlyT1 inhibitors with improved pharmacokinetic properties. Bioorg. Med. Chem. Lett. 2009, 19, 1492–1495. [Google Scholar] [CrossRef] [PubMed]
  20. Chappie, T.A.; Humphrey, J.M.; Allen, M.P.; Estep, K.G.; Fox, C.B.; Lebel, L.A.; Liras, S.; Marr, E.S.; Menniti, F.S.; Pandit, J.; et al. Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors. J. Med. Chem. 2007, 50, 182–185. [Google Scholar] [CrossRef] [PubMed]
  21. Falgueyret, J.P.; Oballa, R.M.; Okamoto, O.; Wesolowski, G.; Aubin, Y.; Rydzewski, R.M.; Prasit, P.; Riendeau, D.; Rodan, S.B.; Percival, M.D. Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L. J. Med. Chem. 2001, 44, 94–104. [Google Scholar] [CrossRef] [PubMed]
  22. Dhameliya, T.M.; Chudasma, S.J.; Patel, T.M.; Dave, B.P. A review on synthetic account of 1,2,4-oxadiazoles as anti-infective agents. Mol. Divers 2022, 26, 2967–2980. [Google Scholar] [CrossRef] [PubMed]
  23. Kayukova, L.A. Synthesis of 1,2,4-oxadiazoles (a review). Pharm. Chem. J. 2005, 39, 539–547. [Google Scholar] [CrossRef]
  24. Szulczyk, D.; Wozinski, M.; Kolinski, M.; Kmiecik, S.; Glogowska, A.; Augustynowicz-Kopec, E.; Dobrowolski, M.A.; Roszkowski, P.; Struga, M.; Ciura, K. Menthol- and thymol-based ciprofloxacin derivatives against Mycobacterium tuberculosis: In vitro activity, lipophilicity, and computational studies. Sci. Rep. 2023, 13, 16328. [Google Scholar] [CrossRef] [PubMed]
  25. McOsker, C.C.; Fitzpatrick, P.M. Nitrofurantoin: Mechanism of action and implications for resistance development in common uropathogens. J. Antimicrob. Chemother. 1994, 33 (Suppl. A), 23–30. [Google Scholar] [CrossRef] [PubMed]
  26. PDB Entry—6YJF. Available online: https://www.wwpdb.org/pdb?id=pdb_00006yjf (accessed on 20 March 2024).
  27. Baretta, K.; Garen, C.; Yin, J.; James, M.N. Expression, purification, crystallization and preliminary crystallographic analysis of the phosphoglycerate kinase from Acinetobacter baumannii. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 2012, 68, 790–792. [Google Scholar] [CrossRef] [PubMed]
  28. Almasaudi, S.B. Acinetobacter spp. as nosocomial pathogens: Epidemiology and resistance features. Saudi J. Biol. Sci. 2018, 25, 586–596. [Google Scholar] [CrossRef] [PubMed]
  29. Tatum, N.J.; Duarte, F.; Kamerlin, S.C.L.; Pohl, E. Relative Binding Energies Predict Crystallographic Binding Modes of Ethionamide Booster Lead Compounds. J. Phys. Chem. Lett. 2019, 10, 2244–2249. [Google Scholar] [CrossRef] [PubMed]
  30. Abuhammad, A.; Fullam, E.; Lowe, E.D.; Staunton, D.; Kawamura, A.; Westwood, I.M.; Bhakta, S.; Garner, A.C.; Wilson, D.L.; Seden, P.T.; et al. Piperidinols that show anti-tubercular activity as inhibitors of arylamine N-acetyltransferase: An essential enzyme for mycobacterial survival inside macrophages. PLoS ONE 2012, 7, e52790. [Google Scholar] [CrossRef] [PubMed]
  31. Abuhammad, A.; Lowe, E.D.; McDonough, M.A.; Shaw Stewart, P.D.; Kolek, S.A.; Sim, E.; Garman, E.F. Structure of arylamine N-acetyltransferase from Mycobacterium tuberculosis determined by cross-seeding with the homologous protein from M. marinum: Triumph over adversity. Acta Crystallogr. D Biol. Crystallogr. 2013, 69, 1433–1446. [Google Scholar] [CrossRef] [PubMed]
  32. Agre, N.; Tawari, N.; Maitra, A.; Gupta, A.; Munshi, T.; Degani, M.; Bhakta, S. 3-(5-Nitrofuran-2-yl)prop-2-en-1-one Derivatives, with Potent Antituberculosis Activity, Inhibit A Novel Therapeutic Target, Arylamine N-acetyltransferase, in Mycobacteria. Antibiotics 2020, 9, 368. [Google Scholar] [CrossRef] [PubMed]
  33. He, X.; Alian, A.; Stroud, R.; Ortiz de Montellano, P.R. Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis. J. Med. Chem. 2006, 49, 6308–6323. [Google Scholar] [CrossRef] [PubMed]
  34. El Sawy, M.A.; Elshatanofy, M.M.; El Kilany, Y.; Kandeel, K.; Elwakil, B.H.; Hagar, M.; Aouad, M.R.; Albelwi, F.F.; Rezki, N.; Jaremko, M.; et al. Novel Hybrid 1,2,4- and 1,2,3-Triazoles Targeting Mycobacterium Tuberculosis Enoyl Acyl Carrier Protein Reductase (InhA): Design, Synthesis, and Molecular Docking. Int. J. Mol. Sci. 2022, 23, 4706. [Google Scholar] [CrossRef] [PubMed]
  35. Kahlmeter, G.; Brown, D.F.; Goldstein, F.W.; MacGowan, A.P.; Mouton, J.W.; Odenholt, I.; Rodloff, A.; Soussy, C.J.; Steinbakk, M.; Soriano, F.; et al. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing. Clin. Microbiol. Infect. 2006, 12, 501–503. [Google Scholar] [CrossRef] [PubMed]
  36. Wiegand, I.; Hilpert, K.; Hancock, R.E. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat. Protoc. 2008, 3, 163–175. [Google Scholar] [CrossRef] [PubMed]
  37. Chuprun, S.; Dar’in, D.; Rogacheva, E.; Kraeva, L.; Levin, O.; Manicheva, O.; Dogonadze, M.; Vinogradova, T.; Bakulina, O.; Krasavin, M. Mutually Isomeric 2- and 4-(3-nitro-1,2,4-triazol-1-yl)pyrimidines Inspired by an Antimycobacterial Screening Hit: Synthesis and Biological Activity against the ESKAPE Panel of Pathogens. Antibiotics 2020, 9, 666. [Google Scholar] [CrossRef] [PubMed]
  38. Jumper, J.; Evans, R.; Pritzel, A.; Green, T.; Figurnov, M.; Ronneberger, O.; Tunyasuvunakool, K.; Bates, R.; Zidek, A.; Potapenko, A.; et al. Highly accurate protein structure prediction with AlphaFold. Nature 2021, 596, 583–589. [Google Scholar] [CrossRef] [PubMed]
  39. Lu, C.; Wu, C.; Ghoreishi, D.; Chen, W.; Wang, L.; Damm, W.; Ross, G.A.; Dahlgren, M.K.; Russell, E.; Von Bargen, C.D.; et al. OPLS4: Improving Force Field Accuracy on Challenging Regimes of Chemical Space. J. Chem. Theory Comput. 2021, 17, 4291–4300. [Google Scholar] [CrossRef]
  40. O’Neill, A.G.; Beaupre, B.A.; Zheng, Y.; Liu, D.; Moran, G.R. NfoR: Chromate Reductase or Flavin Mononucleotide Reductase? Appl. Environ. Microbiol. 2020, 86, e01758-20. [Google Scholar] [CrossRef] [PubMed]
  41. Cellitti, S.E.; Shaffer, J.; Jones, D.H.; Mukherjee, T.; Gurumurthy, M.; Bursulaya, B.; Boshoff, H.I.; Choi, I.; Nayyar, A.; Lee, Y.S.; et al. Structure of Ddn, the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis involved in bioreductive activation of PA-824. Structure 2012, 20, 101–112. [Google Scholar] [CrossRef] [PubMed]
Molecules 29 03364 g001
Figure 1. Some clinical nitrofuran-based antibiotics and most active antitubercular 5-(5-nitrofuran-2-yl)-1,2,4-oxadiazole (MIC = 3.1 μg/mL against M. tuberculosis HRv37 strain); nitrofuranoyl “warhead” marked as red.
Figure 1. Some clinical nitrofuran-based antibiotics and most active antitubercular 5-(5-nitrofuran-2-yl)-1,2,4-oxadiazole (MIC = 3.1 μg/mL against M. tuberculosis HRv37 strain); nitrofuranoyl “warhead” marked as red.
Molecules 29 03364 g001
Molecules 29 03364 sch001
Scheme 1. Synthesis of target compounds. Reagents and conditions: (I) NH2OH (50% aq), MeOH, rt, 12–24 h, 61–93%; (II) 5-nitro-2-furoic acid, CDI, DMF, 0 °C → 90 °C, then HCl (3 M, dioxane), 43–66%.
Scheme 1. Synthesis of target compounds. Reagents and conditions: (I) NH2OH (50% aq), MeOH, rt, 12–24 h, 61–93%; (II) 5-nitro-2-furoic acid, CDI, DMF, 0 °C → 90 °C, then HCl (3 M, dioxane), 43–66%.
Molecules 29 03364 sch001
Molecules 29 03364 g002aMolecules 29 03364 g002b
Figure 2. Ligand interactions diagrams of 2h with AzoR (potential principal target) and NfsB (least likely target for ligand binding): left—AzoR, right—NfsB; (A) P. aeruginosa; (B) S. aureus; (C) A. baumannii.
Figure 2. Ligand interactions diagrams of 2h with AzoR (potential principal target) and NfsB (least likely target for ligand binding): left—AzoR, right—NfsB; (A) P. aeruginosa; (B) S. aureus; (C) A. baumannii.
Molecules 29 03364 g002aMolecules 29 03364 g002b
Molecules 29 03364 g003
Figure 3. Co-factor accessibility for the nitro group in the AzoR structure of (A) A. baumannii; (B) S. aureus; (C) P. aeruginosa; (yellow-colored molecule—2c; violet—2h); FMN in green. Protein-ligand contacts showed by dashed lines: yellow—hydrogen bonds, light blue—pi-stacking, dark green—Pi-cation, magenta—salt bridge.
Figure 3. Co-factor accessibility for the nitro group in the AzoR structure of (A) A. baumannii; (B) S. aureus; (C) P. aeruginosa; (yellow-colored molecule—2c; violet—2h); FMN in green. Protein-ligand contacts showed by dashed lines: yellow—hydrogen bonds, light blue—pi-stacking, dark green—Pi-cation, magenta—salt bridge.
Molecules 29 03364 g003
Molecules 29 03364 g004aMolecules 29 03364 g004b
Figure 4. Interaction of 2k with the most likely A. baumannii targets: left—three-dimensional binding poses models, right—ligand–protein interaction diagram; (A) 2k with Pgk; (B) 2k with AzoR; (C) 2k with NfsB. In the three-dimensional models, the compound under study is shown in gray, the control compounds: A—2~{S})-2-(5-nitrofuran-2-yl)-2,3,5,6,7,8-hexahydro-1~{H}-[1]benzothiolo[2,3-d]pyrimidin-4-one [26]; B, C–nitrofurazone) is shown in yellow.
Figure 4. Interaction of 2k with the most likely A. baumannii targets: left—three-dimensional binding poses models, right—ligand–protein interaction diagram; (A) 2k with Pgk; (B) 2k with AzoR; (C) 2k with NfsB. In the three-dimensional models, the compound under study is shown in gray, the control compounds: A—2~{S})-2-(5-nitrofuran-2-yl)-2,3,5,6,7,8-hexahydro-1~{H}-[1]benzothiolo[2,3-d]pyrimidin-4-one [26]; B, C–nitrofurazone) is shown in yellow.
Molecules 29 03364 g004aMolecules 29 03364 g004b
Molecules 29 03364 g005
Figure 5. (A) Binding pose of 2e (yellow) in Ddn active cavity; (B) ligand interactions diagram of 2e with Ddn. Protein-ligand contacts showed on 3-d model with dashed lines: yellow—hydrogen bonds, light blue—pi-stacking, dark green—Pi-cation, magenta—salt bridge, orange—strained contact.
Figure 5. (A) Binding pose of 2e (yellow) in Ddn active cavity; (B) ligand interactions diagram of 2e with Ddn. Protein-ligand contacts showed on 3-d model with dashed lines: yellow—hydrogen bonds, light blue—pi-stacking, dark green—Pi-cation, magenta—salt bridge, orange—strained contact.
Molecules 29 03364 g005
Molecules 29 03364 g006
Figure 6. Binding poses of the structures studied in complex with EthR protein: (A) 2a (violet); (B) 2g (faded orange); (C) 2d (orange); (D) 2e (yellow). The control structure from PDB is shown in green. Protein-ligand contacts showed on 3-d model with dashed lines: yellow—hydrogen bonds, light blue—pi-stacking, dark green—Pi-cation, magenta—salt bridge, orange—strained contact.
Figure 6. Binding poses of the structures studied in complex with EthR protein: (A) 2a (violet); (B) 2g (faded orange); (C) 2d (orange); (D) 2e (yellow). The control structure from PDB is shown in green. Protein-ligand contacts showed on 3-d model with dashed lines: yellow—hydrogen bonds, light blue—pi-stacking, dark green—Pi-cation, magenta—salt bridge, orange—strained contact.
Molecules 29 03364 g006
Table 1. Antibacterial activity (disk diffusion method inhibition zone (IZ, mm) of compounds 2a–m and nitrofurantoin (NFt) and furazidin (FZ) as positive control against the ESKAPE panel of pathogens. The compounds with broad activity spectra are highlighted by green. The most vulnerable pathogen is highlighted by pink.
Table 1. Antibacterial activity (disk diffusion method inhibition zone (IZ, mm) of compounds 2a–m and nitrofurantoin (NFt) and furazidin (FZ) as positive control against the ESKAPE panel of pathogens. The compounds with broad activity spectra are highlighted by green. The most vulnerable pathogen is highlighted by pink.
ESKAPE
Panel		Compound 2NFtFZ
abcdefghijklm
E. faecium0013 ± 1.607 ± 1.60000000015 ± 1.613 ± 1.0
S. aureus21 ± 1.617 ± 1.021 ± 1.6027 ± 0.421 ± 1.0021 ± 1.62125 ± 1.0015 ± 0.317 ± 1.221 ± 0.323 ± 1.6
K. pneumoniae0025 ± 1.009 ± 1.60017 ± 0.30000012 ± 1.014 ± 1.6
A. baumannii000000023 ± 1.00013 ± 0.10000
P. aeruginosa1500000000000000
E. cloacae01321 ± 1.6000019 ± 0.50000024 ± 0.421 ± 1.0
Table 2. Minimal inhibitory concentration (MIC, µg/mL) of tested compounds and ciprofloxacin (positive control) against the ESKAPE panel of pathogens and MTB; nt—not tested. The MIC values are mean from three different assays (errors were in the range of ±5–10% of the reported values). The MIC values less than positive control are highlighted by green.
Table 2. Minimal inhibitory concentration (MIC, µg/mL) of tested compounds and ciprofloxacin (positive control) against the ESKAPE panel of pathogens and MTB; nt—not tested. The MIC values are mean from three different assays (errors were in the range of ±5–10% of the reported values). The MIC values less than positive control are highlighted by green.
CompoundsPathogens
E. faeciumS. aureusK. pneumoniaeA. baumanniiP. aeruginosaE. cloacaeM. tuberculosis
2c4 ± 0.16 ± 0.60.5 ± 0.132 ± 0.14 ± 0.030.25 ± 0.01100 ± 10.0
2h1 ± 0.030.8 ± 0.011.75 ± 0.50.4 ± 0.19 ± 0.63.5 ± 0.150 ± 3.0
2entntntntntnt6.2 ± 0.4
2dntntntntntnt25 ± 1.8
2f,i,kntntntntntnt50 ± 3.1
2a,b,g,j,l,mntntntntntnt≥100
nitrofurantoin8 ± 0.14 ± 0.164 ± 3.0ntnt4 ± 0.1nt
furazidine32 ± 0.18 ± 0.132 ± 3.0ntnt2 ± 0.1nt
ciprofloxacin1.25 ± 0.11.25 ± 0.10.6 ± 0.12.5 ± 0.10.6 ± 0.13 ± 0.10.5–0.25 [24]
Table 3. Results of molecular docking of the investigated compounds into the active sites of the most likely targets associated with antibiotics of the nitrofuran class, stars indicate the quality of binding pose, where: ***—good, **—fair, *—low. Coloring in «Compounds» column: red—inactive compounds at all targets/species, dark green and faded green—active/moderately active compounds. Coloring in «GlideScore» columns: green—correlated with experiment, yellow—fair correlation, brown—correlation with negative control. n/a—docking pose can’t be obtained.
Table 3. Results of molecular docking of the investigated compounds into the active sites of the most likely targets associated with antibiotics of the nitrofuran class, stars indicate the quality of binding pose, where: ***—good, **—fair, *—low. Coloring in «Compounds» column: red—inactive compounds at all targets/species, dark green and faded green—active/moderately active compounds. Coloring in «GlideScore» columns: green—correlated with experiment, yellow—fair correlation, brown—correlation with negative control. n/a—docking pose can’t be obtained.
CompoundsGlideScore (kcal/mol) and Binding Quality (Stars)
AzoRNfsANfsBPgkDdn
P. aeruginosaS. aureusA. baumanniiP. aeruginosaS. aureusA. baumanniiP. aeruginosaS. aureusA. baumanniiP. aeruginosaS. aureusA. baumanniiM. tuberculosis
2a−7.51 (***)−6.81 (**)−8.44 (***)−5.47 (***)−7.18 (***)−6.15 (***)−5.16 (**)−6.03 (***)−5.41 (*)−6.77 (***)−6.50 (*)−6.88 (***)−6.70 (***)
2c−6.95 (***)−7.53 (***)−7.95 (***)−5.14 (***)−5.83 (***)−6.15 (***)−5.46 (*)−5.75 (**)−5.77 (**)−8.24 (***)−5.52 (*)−8.40 (***)n/a
2d−6.58 (*)−6.81 (*)−6.69 (*)−6.25 (*)−5.89 (*)−6.09 (*)−5.71 (*)−7.20 (*)−5.79 (*)−6.98 (*)−5.99 (*)−6.18 (***)n/a
2e−8.89 (***)−8.28 (**)−9.23 (*)−4.77 (*)−6.02 (*)−5.40 (***)−7.04 (*)−6.63 (**)−5.35 (*)−8.38 (***)−6.71 (*)−7.57 (**)−7.74 (***)
2f−6.51 (*)−7.87 (***)−8.24 (***)−4.79 (*)−6.60 (*)−6.78 (***)−6.44 (**)−7.61 (***)−5.24 (*)−8.55 (***)−7.32 (*)−8.65 (***)−6.01 (*)
2g−7.59 (*)−8.64 (*)−7.24 (*)−5.63 (*)−5.82 (*)−7.05 (*)−5.88 (*)−6.16 (*)−5.83 (*)−7.00 (**)−6.91 (*)−6.45 (***)n/a
2h−7.46 (***)−7.11 (***)−7.48 (***)−5.13 (***)−7.19 (***)−6.94 (***)−4.60 (**)−5.98 (***)−5.07 (*)−6.60 (***)−7.16 (*)−7.02 (***)n/a
2i−6.09 (***)−7.01 (***)−7.83 (***)−4.77 (*)−7.03 (***)−6.35 (***)−7.16 (**)−7.43 (***)−7.20 (*)−6.98 (***)−5.79 (*)−8.13 (***)−5.83 (***)
2j−6.37 (***)−7.40 (**)−7.89 (***)−4.57 (*)−6.62 (**)−7.06 (**)−5.63 (**)−6.21 (***)−6.11 (*)−7.06 (***)−6.28 (*)−6.46 (***)−6.54 (***)
2k−7.25 (***)−7.55 (**)−6.14 (***)−5.32 (*)−5.90 (*)−4.66 (*)−5.86 (*)−6.67 (***)−7.24 (*)−7.65 (***)−6.98 (*)−8.14 (***)−5.80 (***)
Table 4. Results of molecular docking of tested compounds with proteins considered as promising targets for tuberculosis therapy. Stars indicate the quality of binding pose, where: ***—good, **—fair, *—low. Active compounds highlighted by green, most active highlighted by dark green. N/A—binding pose can’t be calculated.
Table 4. Results of molecular docking of tested compounds with proteins considered as promising targets for tuberculosis therapy. Stars indicate the quality of binding pose, where: ***—good, **—fair, *—low. Active compounds highlighted by green, most active highlighted by dark green. N/A—binding pose can’t be calculated.
GlideScore (kcal/mol)/Quality of Binding Pose (Stars)
Protein2a2c2d2e2g2h2kControl
EthR−8.67 (*)−7.80 (**)−7.47 (**)−10.32 (***)−7.66 (*)−8.05 (**)−8.29 (**)−10.80 (***)
TBNAT−5.86 (*)−4.91 (*)−5.22 (**)−5.85 (**)−6.39 (*)−4.70 (**)−4.88 (*)N/A
InhA−7.23 (***)−6.57 (***)−5.57 (*)−7.66 (***)−6.23 (*)−6.86 (***)−7.20 (***)−9.70 (***)
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Vinogradova, L.; Lukin, A.; Komarova, K.; Zhuravlev, M.; Fadeev, A.; Chudinov, M.; Rogacheva, E.; Kraeva, L.; Gureev, M.; Porozov, Y.; et al. Molecular Periphery Design Allows Control of the New Nitrofurans Antimicrobial Selectivity. Molecules 2024, 29, 3364. https://doi.org/10.3390/molecules29143364

AMA Style

Vinogradova L, Lukin A, Komarova K, Zhuravlev M, Fadeev A, Chudinov M, Rogacheva E, Kraeva L, Gureev M, Porozov Y, et al. Molecular Periphery Design Allows Control of the New Nitrofurans Antimicrobial Selectivity. Molecules. 2024; 29(14):3364. https://doi.org/10.3390/molecules29143364

Chicago/Turabian Style

Vinogradova, Lyubov, Alexey Lukin, Kristina Komarova, Maxim Zhuravlev, Artem Fadeev, Mikhail Chudinov, Elizaveta Rogacheva, Lyudmila Kraeva, Maxim Gureev, Yuri Porozov, and et al. 2024. "Molecular Periphery Design Allows Control of the New Nitrofurans Antimicrobial Selectivity" Molecules 29, no. 14: 3364. https://doi.org/10.3390/molecules29143364

APA Style

Vinogradova, L., Lukin, A., Komarova, K., Zhuravlev, M., Fadeev, A., Chudinov, M., Rogacheva, E., Kraeva, L., Gureev, M., Porozov, Y., Dogonadze, M., & Vinogradova, T. (2024). Molecular Periphery Design Allows Control of the New Nitrofurans Antimicrobial Selectivity. Molecules, 29(14), 3364. https://doi.org/10.3390/molecules29143364

Article Metrics

Back to TopTop